

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

A2780

RRID:CVCL_0134

Type: Cell Line

Proper Citation

RRID:CVCL_0134

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0134

Proper Citation: RRID:CVCL_0134

Description: Cell line A2780 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian endometrioid adenocarcinoma

Defining Citation: [PMID:1348364](#), [PMID:1999494](#), [PMID:2429947](#), [PMID:2751261](#), [PMID:3335022](#), [PMID:3539322](#), [PMID:3986765](#), [PMID:6173755](#), [PMID:6372095](#), [PMID:6954533](#), [PMID:7927910](#), [PMID:8012063](#), [PMID:8557231](#), [PMID:9041185](#), [PMID:11103784](#), [PMID:11416159](#), [PMID:12080474](#), [PMID:15677628](#), [PMID:18273836](#), [PMID:19714814](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:22328975](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22705003](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25846456](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27235858](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:28546799](#), [PMID:30485824](#), [PMID:30894224](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:33287223](#), [PMID:34071702](#), [PMID:35839778](#), [PMID:36476833](#)

Comments: Population: African American., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A2780

Synonyms: A-2780, 2780, A2780S, A2780par

Cross References: BTO:BTO_0002549, CLO:CLO_0001571, EFO:EFO_0006362, MCCL:MCC:0000027, CLDB:cl193, CLDB:cl194, CLDB:cl4894, ABM:T8089, AddexBio:C0017002/20, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BCRJ:0031, BioGRID_ORCS_Cell_line:329, BioSample:SAMN03472806, BioSample:SAMN10988216, cancercellines:CVCL_0134, CancerTools:152706, Cell_Model_Passport:SIDM00210, ChEMBL-Cells:ChEMBL3308421, ChEMBL-Targets:ChEMBL614004, CLS:300491, Cosmic:688090, Cosmic:755844, Cosmic:849607, Cosmic:906804, Cosmic:923108, Cosmic:948284, Cosmic:987394, Cosmic:1093558, Cosmic:1102819, Cosmic:1139223, Cosmic:1198265, Cosmic:1305309, Cosmic:1609529, Cosmic:1707564, Cosmic:1708387, Cosmic:1709251, Cosmic:1945872, Cosmic:1995331, Cosmic:2582805, Cosmic:2674698, Cosmic-CLP:906804, DepMap:ACH-000657, ECACC:93112519, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906804, GEO:GSM184388, GEO:GSM184389, GEO:GSM383925, GEO:GSM503257, GEO:GSM659370, GEO:GSM711722, GEO:GSM827312, GEO:GSM851909, GEO:GSM886853, GEO:GSM887918, GEO:GSM1001419, GEO:GSM1001420, GEO:GSM1001488, GEO:GSM1291126, GEO:GSM1291129, GEO:GSM1340577, GEO:GSM1374380, GEO:GSM1374381, GEO:GSM1669581, GEO:GSM2474971, GEO:GSM4845007, GEO:GSM4845008, GEO:GSM6065211, GEO:GSM6065212, GEO:GSM6065213, IARC_TP53:21161, ICLC:HTL98008, LiGeA:CCL_809, LINCS_LDP:LCL-1518, Lonza:207, MetaboLights:MTBLS156, MetaboLights:MTBLS1014, NCI-DTP:A2780, PharmacDB:A2780_40_2019, PRIDE:PXD001176, PRIDE:PXD003105, PRIDE:PXD003252, PRIDE:PXD003668, PRIDE:PXD013811, PRIDE:PXD030304, Progenetix:CVCL_0134, PubChem_Cell_line:CVCL_0134, Wikidata:Q54606559, Ximbio:152706

ID: CVCL_0134

Record Creation Time: 20220427T215105+0000

Record Last Update: 20260904T021133+0000

Ratings and Alerts

No rating or validation information has been found for A2780.

No alerts have been found for A2780.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2271 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. *Cancer research*, 86(9), 2161.

Huang B, et al. (2026) The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. *Cell death & disease*, 17(1), 202.

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. *Science advances*, 12(16), eaeb0855.

Li T, et al. (2026) Overexpression of SLC44A4 suppresses ferroptosis and reduces lipid peroxidation via noncanonical NF- κ B signaling in a NIK-dependent manner. *Annals of medicine*, 58(1), 2677931.

Zhang L, et al. (2026) Four New Dibenzo- β -pyrones From *Helicosporium sessuale* LZ15. *Chemistry & biodiversity*, 23(4), e71229.

Jian X, et al. (2026) Isolation, Identification, and in Vitro Antitumor Activity of Polyphenols From *Euryale ferox* Salisb. *Shell. Chemistry & biodiversity*, 23(1), e03188.

Mohiuddin TM, et al. (2026) Synthetic zipper mediated pre-targeting system for near-infrared photoimmunotherapy. *iScience*, 29(2), 114558.

Hassan NA, et al. (2026) Malformin A1-mediated cytotoxicity in ovarian cancer cells occurs through pyroptosis and autophagy. *FEBS open bio*.

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. *Cell reports methods*, 101515.

Silva JG, et al. (2026) Amides Derived From Sclareolide as Cytotoxic Agents. *Chemistry & biodiversity*, 23(7), e71375.

Rivera M, et al. (2026) APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. *Scientific reports*, 16(1), 5194.

Ma Y, et al. (2026) Large-Scale Quantitative Morphometry of Platelet α -Granules via SIM Super-Resolution Microscopy for Cancer Liquid Biopsy. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(34), e75094.

Uno K, et al. (2026) Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. *Science advances*, 12(6), eadu5944.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Lin C, et al. (2026) Enterolactone and THBS1-3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment. *British journal of pharmacology*, 183(11), 2837.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Santer FR, et al. (2026) Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. *Scientific reports*, 16(1).

Zhu Y, et al. (2026) Targeting Oncogenic lncRNA KRT7-AS to Induce Ferroptosis Suppresses Ovarian Cancer Progression. *Oncology research*, 34(5), 29.

Min Y, et al. (2026) The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer. *Cells*, 15(10).

Zhang X, et al. (2026) Do G4 ligands induce mitochondrial dysfunction without ROS induction. *iScience*, 29(6), 116036.